STX-001

STX-001 is a self-replicating mRNA in lipid nanoparticle (intratumoural) from Strand Therapeutics. A lipid nanoparticle-encapsulated self-replicating mRNA that makes tumour cells express interleukin-12, injected into tumours. Its furthest stage is phase 1, for melanoma, advanced solid tumours, triple-negative breast cancer and head and neck cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 recruiting since May 2024 (registry), alone and with pembrolizumab. Whether it works in people has not been established unless a trial below reports it.